Cell and Molecular Biology Research Program

项目摘要/摘要 细胞和分子生物学计划 埃默里大学温希普癌症研究所细胞和分子生物学(CMB)项目 开展高度创新的基础性和转化性研究，重点关注集水领域的优先事项。 成立于2019年，由以前的癌症遗传学和表观遗传学(CGE)和癌细胞生物学重组而成 (CCB)计划纳入一个研究计划，CMB的科学主题是：(1)癌细胞代谢的目标 揭开癌细胞代谢变化的分子机制以开发新的 治疗干预；(2)细胞存活和死亡机制旨在了解 癌细胞逃避细胞死亡和寻找促进细胞死亡的新的治疗方法；(3)机制 侵袭和转移学的目标是确定肿瘤生长和转移的关键介质，并发现 驱动肿瘤细胞黏附、通讯、侵袭和转移的机制，以及；(4)基因调控 旨在破译遗传或表观遗传影响调节基因表达和 有助于肿瘤的发生。招商银行领导营造丰富的科研培训环境，助力推广 在从中学到大学的代表性不足的群体中，生物医学科学职业的比例。中巴维持 通过与社区外展的密切接触，重点研究Winship的集水区优先事项 和参与度(COE)。在周伟博士(组长)和屈振坤博士(医学博士，联席组长)的领导下， 新的CMB计划包括46名核心成员，代表医学院内的16个系 (SOM)、公共卫生学院和文理学院。这个高度协作的小组 在当前的资助期间，研究人员共发表了317篇与癌症有关的科学文章。 其中42(13%)为方案内协作，139(44%)为方案间协作，234(74%)为机构间协作，94 (30%)发表在影响因子为≥10的期刊上。截至2021年12月31日，招商银行成员持有10.0美元 百万美元(直接)的年度癌症相关研究资金，其中940万美元是由同行评审的 450万美元(47%)来自NCI。筹资周期取得的显著成就包括21个新的R01 已发展为有影响力的CMB科学贡献的赠款(11 NCI)，包括：i)来妥替尼作为 新的MAST-1抑制剂，ii)用于抗转移靶点发现的创新的“领头细胞”鉴定和iii) 一种新的果蝇胶质瘤模型的试点资助基础研究进展到I/II期临床 试验，以及iv)MCL1抑制剂AZD5991的临床前开发，导致在 温希普。招商银行从Winship的共享资源、基础和翻译基础设施中受益匪浅 研究，在本供资期间提供210万美元的试点赠款支助，并参与团队科学 CMB成员领导P50肺孢子和新P01(2022年5月)用于LKB1-研究的环境- 突变的肺癌。招商银行准备通过了解细胞和 癌症的分子机制和驱动新的治疗方法。

PROJECT SUMMARY/ABSTRACT CELL AND MOLECULAR BIOLOGY PROGRAM The Cell and Molecular Biology (CMB) Program of Winship Cancer Institute of Emory University (Winship) conducts highly innovative basic and translational research with a strong focus on catchment area priorities. Formed in 2019 by restructuring the previous Cancer Genetics and Epigenetics (CGE) and Cancer Cell Biology (CCB) programs into one research program, the scientific themes of CMB are: (1) Cancer Cell Metabolism aims to unravel the molecular mechanisms underlying metabolic alterations in cancer cells to exploit for novel therapeutic interventions; (2) Cell Survival and Death Mechanisms aims to understand the mechanisms by which cancer cells evade cell death and to identify novel therapeutic approaches to promote cell death; (3) Mechanisms of Invasion and Metastasis aims to identify the key mediators of tumor growth and metastasis, and discover mechanisms that drive tumor cell adhesion, communication, invasion, and metastasis, and; (4) Gene Regulation aims to decipher the basic mechanisms by which genetic or epigenetic influences regulate gene expression and contribute to oncogenesis. CMB leaders foster a rich research training environment contributing to the promotion of biomedical scientific careers in underrepresented groups from middle school through college. CMB maintains research focus on Winship’s catchment area priorities through strong engagement with Community Outreach and Engagement (COE). Under the leadership of Wei Zhou, PhD (leader) and C.K. Qu, MD, PhD (co-leader), the new CMB Program includes 46 core members representing 16 departments within the School of Medicine (SOM), School of Public Health, and College of Arts and Sciences. This highly collaborative group of researchers have published a total 317 cancer-relevant scientific articles during the current funding period with 42 (13%) intra- and 139 (44%) inter-programmatic, 234 (74%) inter-institutional collaborations, and 94 (30%) published in journals with an impact factor ≥10. As of December 31, 2021, CMB members held $10.0 million (direct) in annual cancer-relevant research funding, of which $9.4 million is peer-reviewed with $4.5 million (47%) from the NCI. Notable accomplishments during the funding cycle include 21 new R01 grants (11 NCI) that have developed into impactful CMB scientific contributions including: i) lestaurtinib as a new MAST-1 inhibitor, ii) innovative “leader cell” identification for anti-metastasis target discovery and iii) advancement of pilot grant funded basic research with a novel Drosophila glioma model to a phase I/II clinical trial, and iv) pre-clinical development of the MCL1 inhibitor AZD5991 leading to first-in-human clinical trial at Winship. CMB has greatly benefited from Winship’s shared resources, infrastructure for basic and translational research, $2.1 million in pilot grant support during the present funding period, and engaging team science environment with CMB member leadership in P50 Lung SPORE and new P01 (May 2022) for research on LKB1- mutated lung cancer. CMB is poised to make transformational contributions through understanding cellular and molecular mechanisms underlying cancer and drive novel therapeutic approaches.